<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Institute of Membrane &amp; Systems Biology</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BEF9C85-C0F9-4E41-9E57-1E414C63DC8F"><gtr:id>6BEF9C85-C0F9-4E41-9E57-1E414C63DC8F</gtr:id><gtr:firstName>A</gtr:firstName><gtr:surname>Duke</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AA71F290-7AA5-428F-B57A-936B0C04B5AA"><gtr:id>AA71F290-7AA5-428F-B57A-936B0C04B5AA</gtr:id><gtr:firstName>Derek</gtr:firstName><gtr:otherNames>S</gtr:otherNames><gtr:surname>Steele</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EE9CCCC4-B178-4321-880A-74AEE2239885"><gtr:id>EE9CCCC4-B178-4321-880A-74AEE2239885</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Hopkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601243"><gtr:id>E075A138-A974-41D9-B66A-6599AF4F37C7</gtr:id><gtr:title>The role of store-operated Ca2+ entry in human malignant hyperthermia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601243</gtr:grantReference><gtr:abstractText>Malignant hyperthermia is an inherited condition, which results in a rise in body temperature during anaesthesia. Although this is a relatively infrequent complication of anaesthesia, the rise in temperature is invariably fatal unless treated rapidly and most of those who die are healthy teenagers or young adults. There is a considerable cost to the NHS associated with diagnosis, treatment, training of staff and the avoidance of cost effective anaesthetics, which are potent triggers of the condition. The muscle contraction associated with malignant hyperthermia is known to result from a rise in the level of calcium ions within the tissue. Until very recently, it was believed that all of this calcium was derived from stores located within the muscle itself, and a particular protein (the ryanodine receptor) has been the main focus of study. However, recent work suggests that, in some circumstances, calcium may flood into the cell to induce contraction, and it is possible that this newly discovered mechanism may play a role in malignant hyperthermia. The aim of the present study is to examine whether calcium does enter the cell during human malignant hyperthermia and the properties of this calcium entry mechanism. This is important work, because treatment and the development of non-invasive diagnostic methods require a more complete understanding of the underlying mechanisms and the components of the muscle which exhibit abnormal behaviour during malignant hyperthermia.</gtr:abstractText><gtr:technicalSummary>Malignant hyperthermia (MH) is an adverse reaction to volatile anaesthetics, characterised by skeletal muscle contracture and a potentially fatal rise in core body temperature. While the incidence of MH is relatively low, there are substantial cost implications for the NHS. Most MH cases occur due to mutations in the sarcoplasmic reticulum (SR) Ca2+ channel (RyR1), which increase the sensitivity of the channel to activation by volatile anaesthetics, resulting in a sustained rise in [Ca2+]i. However, recent work on normal muscle from animals has demonstrated the presence of a ?store operated Ca2+ entry? (SOCE) mechanism, activated by depletion of SR Ca2+. Furthermore, experiments on cultured myotubes have identified another mechanism, excitation-coupled Ca2+ entry (ECCE), which may also be relevant to MH. These findings represent a conceptual step-change in our understanding of skeletal muscle function, with potential implications for MH. In the proposed study, we will use isolated human fibres and fibres isolated from a mouse model of MH to test the hypotheses that: (i) SOCE and/or ECCE can be demonstrated in adult human skeletal muscle fibres; (ii) SOCE and/or ECCE mechanisms are more sensitive in human MH muscle than normal muscle; (iii) in MH, the rise in [Ca2+]i following RyR1 activation is exacerbated by SOCE; (iv) in a knock-in murine model of MH changes in SOCE/ECCE characteristics can be attributed to single base changes in the RYR1 gene.</gtr:technicalSummary><gtr:fund><gtr:end>2008-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>194977</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FC51B0AD-3C29-43AF-9734-DC2B4FBA3351</gtr:id><gtr:title>Store-operated Ca2+ entry in malignant hyperthermia-susceptible human skeletal muscle.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b174727b9414b93999c4be54b1324a84"><gtr:id>b174727b9414b93999c4be54b1324a84</gtr:id><gtr:otherNames>Duke AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>RrmRUf1pgGa</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601243</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>